Startup · Healthcare
Melbourne, VIC
Every investor coverage indicates participated in a round Peplin Inc raised.
| Investor | Rounds | Invested |
|---|---|---|
| Asia Union Investments | Unnamed stage | - |
| GBS Venture Partners Ltd. | Unnamed stage | - |
| MPM Capital | Unnamed stage | - |
| New Enterprise Associates | Unnamed stage | - |
| Orbis Funds Management | Unnamed stage | - |
The transaction that ended Peplin Inc's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| LEO Pharma A/S | Acquisition | 3 Sep 2009 | ~$348.4m | GBS Ventures (Tue 25 May 2010), GBS Ventures (Thu 12 Nov 2009), GBS Ventures (Thu 3 Sep 2009), GBS Ventures (Thu 3 Sep 2009) |
Companies Peplin Inc acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Cherrell Hirst | Director | GBS Ventures |
| Dr Eugene Bauer | President and Chief Medical Officer | GBS Ventures (Thu 12 Nov 2009), GBS Ventures (Mon 18 Aug 2008) |
| Dr Joshua Funder | Director (former) | GBS Ventures (Thu 3 Sep 2009), GBS Ventures (Mon 18 Aug 2008) |
| Dr Peter Welburn | Australian General Manager | GBS Ventures (Thu 12 Nov 2009), GBS Ventures (Tue 19 May 2009), GBS Ventures (Thu 8 Jan 2009) |
| Michael Aldridge | CEO (former) | GBS Ventures (Tue 25 May 2010), GBS Ventures (Mon 18 Aug 2008) |
| Tom Wiggans | Chairman and CEO | GBS Ventures (Thu 3 Sep 2009), GBS Ventures (Thu 23 Jul 2009), GBS Ventures (Tue 19 May 2009), GBS Ventures (Thu 8 Jan 2009), GBS Ventures (Tue 16 Dec 2008), GBS Ventures (Mon 18 Aug 2008), GBS Ventures (Mon 18 Aug 2008) |
Stories naming Peplin Inc. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures marks its fourth FDA drug approval as Hatchtech's head lice treatment Xeglyze clears the regulator, recalling earlier wins behind Picato, Synribo and Aridol with Australian biotech firms.
Leo Pharma has agreed a US$287.5m cash takeover of Peplin, the ASX-listed skin-disease drug developer in GBS Ventures' portfolio; GBS recalls leading its late-2008 round alongside two American venture backers.
LEO Pharma has struck a deal to buy ASX-listed Peplin for roughly US$287.5 million, with its two biggest shareholders, including GBS Venture Partners, backing the transaction.
Peplin has begun a second Phase 3 trial of its skin-lesion gel, seeking to confirm earlier clearance results at non-head sites, with a regulatory filing planned for mid-2010.
A Brisbane skin-cancer biotech reports successful late-stage results for its sun-spot gel, saying it remains on schedule for a US regulatory filing and a 2011 market launch.
Peplin reports its PEP005 gel met the primary endpoint in a Phase IIb actinic keratosis trial, clearing lesions safely across doses and moving toward Phase III development.
ASX-listed biotech Peplin has finished enrolling 250 patients in the first Phase III trial of its PEP005 Gel treatment for actinic keratosis, with results expected in H1 2009.
Peplin hires Tom Wiggans as CEO and Eugene Bauer as President/CMO while Michael Aldridge steps down; the dermatology company also announces a US$24m capital raising and a merger agreement with Neosil.
Also GBS Ventures